Fundación Santa Fe de Bogotá, Universidad de Los Andes, Bogotá, Colombia.
Adv Ther. 2019 Mar;36(Suppl 1):20-25. doi: 10.1007/s12325-019-0884-4. Epub 2019 Feb 13.
Chronic venous disease (CVD) is both prevalent and unavoidable in many people as a result of persistent or unalterable risk factors, the most important of which are advanced age, excess body weight, and family history. Given this inevitability, medical treatment is required to alleviate symptoms and slow disease progression. Venoactive drug therapy is emerging as a valuable treatment option for many CVD patients and micronized purified flavonoid fraction (MPFF) is the most widely prescribed and well-studied venoactive drug available. Recent evidence from animal models of venous hypertension and from clinical trials, as well as from systematic reviews, shows that MPFF is effective at alleviating many of the most common symptoms of CVD including leg pain, leg heaviness, sensations of swelling, cramps, and functional discomfort. In addition, MPFF improves the clinical signs of redness, skin changes, and edema, and improves quality of life. Collectively, these findings support the strong recommendation for MPFF treatment found in the 2018 international guidelines for the management of CVD.Funding: Servier.
慢性静脉疾病（CVD）在许多人中普遍存在且不可避免，这是由于持续存在或无法改变的风险因素所致，其中最重要的是年龄较大、超重和家族史。鉴于这种必然性，需要进行医疗治疗以缓解症状和减缓疾病进展。静脉活性药物治疗作为许多 CVD 患者的有价值的治疗选择正在出现，而微粒化纯化黄酮类混合物（MPFF）是最广泛开处方和研究最多的静脉活性药物。最近来自静脉高血压动物模型和临床试验以及系统评价的证据表明，MPFF可有效缓解 CVD 最常见的许多症状，包括腿部疼痛、腿部沉重感、肿胀感、痉挛和功能不适。此外，MPFF改善了红斑、皮肤变化和水肿的临床体征，并改善了生活质量。综上所述，这些发现支持 2018 年 CVD 管理国际指南中发现的对 MPFF 治疗的强烈推荐。资金来源：Servier。
